
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| REGLAN | ANI Pharmaceuticals | N-017854 RX | 1982-01-01 | 2 products, RLD, RS |
| GIMOTI | Evoke Pharma | N-209388 RX | 2020-06-19 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| gimoti | New Drug Application | 2021-01-07 |
| metoclopramide | ANDA | 2025-12-04 |
| metoclopramide hydrochloride | ANDA | 2025-11-12 |
| reglan | New Drug Application | 2020-06-19 |
Code | Description |
|---|---|
| J2765 | Injection, metoclopramide hcl, up to 10 mg |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | — | R11.1 | — | — | 1 | 2 | — | 3 |
| Neoplasms | D009369 | — | C80 | — | — | — | 1 | — | 1 |
| Nausea | D009325 | — | R11.0 | — | — | — | 1 | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | 1 | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | 1 | — | 1 |
| Drug common name | Metoclopramide |
| INN | metoclopramide |
| Description | Metoclopramide is a member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine. It has a role as an antiemetic, a dopaminergic antagonist, a gastrointestinal drug, a xenobiotic and an environmental contaminant. It is a tertiary amino compound, a substituted aniline, a member of benzamides and a member of monochlorobenzenes. It is a conjugate base of a metoclopramide(1+). |
| Classification | Small molecule |
| Drug class | D2 receptor antagonist; 5-HT3 receptor antagonist; 5-HT4 receptor agonist; Prolactin releaser |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC |
| PDB | — |
| CAS-ID | 364-62-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL86 |
| ChEBI ID | 107736 |
| PubChem CID | 4168 |
| DrugBank | DB01233 |
| UNII ID | L4YEB44I46 (ChemIDplus, GSRS) |






